335155-20-9

Upstream product

• 1701-57-1 2,3,4,5-tetrahydro-1Hbenzo[b]azepine 
• 1160759-52-3 4-cyano-3-methylbenzoyl chloride 
• 1122-58-3 dmap 
• 73831-13-7 4-cyano-3-methylbenzoic acid 

Downstream Products

• 1092844-49-9 1-(4-cyano-3-methylbenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 736127-06-3 1-[2-methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-ylcarbonyl)-phenyl]methanamine 
• 335155-21-0 1-(4-(Aminomethyl)-3-methylbenzoyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride 

Relevant academic research and scientific papers

Subtlety of the Structure-Affinity and Structure-Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist

Very few nonpeptide oxytocin agonists have currently been reported, and none of them seem suitable for the in vivo investigation of the oxytocin mediated functions. In an attempt to rationalize the design of better tools, we have systematically studied the structural determinants of the affinity and efficacy of representative ligands of the V1a, V2, and OT receptor subtypes. Despite apparently obvious similarity between the ligand structures on one hand, and between the receptor subtypes on the other hand, the binding affinity and the functional activity profiles of truncated and hybrid ligands highlight the subtlety of ligand-receptor interactions for obtaining nonpeptide OT receptor agonists.

Condensed azepines as vasopressin agonists

This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, O